Exploring Psilocybin's Safety in Clinical Trials

The Dales Report

2024-04-15

Exploring Psilocybin’s Safety in Clinical Trials

Recent studies highlight psilocybin’s potential in mental health treatment, emphasizing its safety and effectiveness.

Check it out!

Related News

Live and Awake in LA

Having attended the surprisingly few SoCal events over the past few years, it was such a welcome pleasure to see familiar faces coming together in LA for 3 days of meaningful conversations centered around healing, community, access, learning, and networking at Psychedelic Awakening 2025 hosted by Psychedelic Institute of Los Angeles.

Psychedelic Science 2025: Set and (Re)Setting

For its fifth installment, Psychedelic Science 2025 returned to Denver, offering three days of big ideas, heartfelt community, and some noticeable shifts in the psychedelic space. After the usual chaos of delayed flights and travel drama on Tuesday, we shared a collective sigh of relief as we finally arrived at the Colorado Convention Center, a mile high and ready to dive in.

New Paul Stamets Psychedelic Microdosing Study with MindMed and Numi Connections | New DMT Study

In this episode of the $Psyc Business Roundup, we’ll cover Algernon Pharmaceuticals (OTC: AGNPF, CSE: AGN) is planning to begin a clinical trial using DMT to treat acute strokes.

5 Athletes Who Healed With Psychedelic Therapy

Conventional mental health therapies have offered little help. But a growing number of professional athletes are finding the path back to a better life with a more unconventional therapy—psychedelics. These five athletes are leading the way in psychedelic therapy.

Could Psilocybin End Our Addiction Crisis?

Two doses of psilocybin over a period of eight weeks significantly reduced alcohol use and cravings for alcoholics. That’s according to early results of a New York University phase 2 study.